Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBITDA Margin (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed EBITDA Margin for 11 consecutive years, with 415.97% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 60617.0% to 415.97% in Q4 2025 year-over-year; TTM through Dec 2025 was 609.22%, a 28628.0% increase, with the full-year FY2025 number at 609.22%, up 28628.0% from a year prior.
  • EBITDA Margin was 415.97% for Q4 2025 at Intellia Therapeutics, up from 732.75% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6825.61% in Q4 2023 to a low of 23935.0% in Q3 2021.
  • A 5-year average of 1674.94% and a median of 800.81% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -2380915bps in 2021, then soared 2308287bps in 2022.
  • Intellia Therapeutics' EBITDA Margin stood at 651.12% in 2021, then dropped by -26bps to 821.48% in 2022, then surged by 931bps to 6825.61% in 2023, then crashed by -115bps to 1022.14% in 2024, then skyrocketed by 59bps to 415.97% in 2025.
  • Per Business Quant, the three most recent readings for NTLA's EBITDA Margin are 415.97% (Q4 2025), 732.75% (Q3 2025), and 713.65% (Q2 2025).